PTNR-TM 007

PTNR-TM 007 is an investigational drug candidate being developed by Vivera Biosciences (a division of Vivera Pharmaceuticals) in collaboration with an undisclosed third-party partner for the treatment of central nervous system (CNS) disorders. The candidate is formulated using Vivera's proprietary TABMELT sublingual drug delivery technology, which allows the medication to dissolve rapidly under the tongue. This sublingual route is designed to bypass gastrointestinal absorption and first-pass hepatic metabolism, potentially offering faster onset of action, more consistent bioavailability, and improved patient compliance compared to traditional oral dosage forms.

Other names

PTNR-TM-007PTNR-TM007PTNR-TM 007